EUVIMED · CrossrefJournal
Journal of Enzyme Inhibition and Medicinal Chemistry
ISSN 1475-6366 · Informa UK Limited
Latest articles
Discovery of novel N-(prop-2-yn-1-yl)-1,2,3,4-tetrahydronaphthalen-1-amine derivatives as MAO-B inhibitors for the treatment of Parkinson’s disease
Identification of a peptide inhibitor disrupting the PCSK9-LDLR interaction via pharmacophore-based virtual screening, molecular dynamics simulations and in vitro/vivo evaluation
Diethyl Phthalate (DEP) as a potential osteosarcoma risk factor: a multi-omics study integrating network Toxicology, single-cell RNA sequencing, and molecular docking
Synthetic strategies and therapeutic insights into FDA-approved indole-containing drugs
Discovery of novel coumarin-containing triazolo[1,5-a]pyrimidine derivatives as potent ABCB1 inhibitor for modulation of multidrug resistance
Reactive oxygen species (ROS) research in drug discovery and drug delivery: Can the medium Be a Trojan Horse disguised as something benign?
Synthesis and structure-activity relationship study of a library of 1-substituted [1,2,4]triazolo[4,3- a ]quinolines as valuable chemical probes for paraxonase-2 (PON2)
Discovery of ferulic acid carbamate derivatives as dual-targeting agents of BuChE and Nrf2 for Alzheimer’s disease
2 H -pyrazolo[3,4- d ]pyrimidin-4-amine derivatives as novel selective fibroblast growth factor receptor 2 (FGFR2) inhibitors
Mechanisms of traditional Chinese medicine in enhancing the efficacy and reducing the toxicity of immune checkpoint inhibitors via regulation of the tumor microenvironment and gut microbiota
Structural optimization of CHI3L1 inhibitors with improved pharmacokinetics and functional activity in 3D glioblastoma models
Inflammation and carcinogenesis: molecular targets and small-molecule intervention strategies
Identification, optimisation, and structural elucidation of chloroacetamide scaffold as covalent inhibitors for ubiquitin C-terminal Hydrolase L3
The new thiazolidine-2,4-dione-based hybrids with promising antimycobacterial activity: design, synthesis, biological evaluation, and drug interaction analysis
Discovery of novel biphenyl compounds bearing hydroxamic acid moiety as the first PD-L1/class I HDACs dual inhibitors
Identification of novel inhibitors of dengue viral NS5 RNA-dependent RNA polymerase through molecular docking, biological activity evaluation and molecular dynamics simulations
Fourth-generation EGFR-TKI to overcome C797S mutation: past, present, and future
Medicinal chemistry breakthroughs on ATM, ATR, and DNA-PK inhibitors as prospective cancer therapeutics
Profiling and cheminformatics bioprospection of curcurbitacin I and momordin Ic from Momordica balsamina on α-amylase and α-glucosidase
Liquidambaric acid as a non-competitive α-glucosidase inhibitor: multi-level evidence from enzyme kinetics, molecular docking, molecular dynamics simulations, and a Drosophila hyperglycaemic model
Synthesis, in vitro and in silico studies of a novel chrysin-ferrocene Schiff base with potent anticancer activity via G1 arrest, caspase-dependent apoptosis and inhibition of topoisomerase II
Design, synthesis, and antiproliferative activity of new 5-ethylsulfonyl-indazole-3-carbohydrazides as dual EGFR/VEGFR-2 kinases inhibitors
Development of novel benzamide class I selective lysine deacetylase inhibitors as potent anticancer agents
Development of eugenol derivatives with 5-LOX inhibitory activity
FDA-approved kinase inhibitors in PROTAC design, development and synthesis
The key enzyme PYCR1 in proline metabolism: a dual driver of cancer progression and fibrotic remodeling
Biotin-mediated drug delivery: does the biotin transporter mediate uptake of biotin conjugates?
Advances in ERK1/2 inhibition: a medicinal chemistry perspective on structure and regulation
Targeting RIPK1 to modulate cell death and tumour microenvironment in cancer therapy
Identification of novel PTP1B inhibitor for the treatment of LPS-induced myocardial apoptosis: machine learning based virtual screening and biological evaluation
EUVIMED